BfArM - Federal Institute for Drugs and Medical Devices

Dear Doctor Letter (Rote-Hand-Brief) on Nplate^® (romiplostim): Risk of disease progression of pre-existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)

2011.09.16

Active substance: romiplostim

Important safety-relevant information on the risk of disease progression to an acute myeloid leukemia with romiplostin (Nplate®) use in patients with myelodysplastic syndrome (MDS).

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN 2011.09.16 PDF, 427KB, File is accessible

BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Nplate^® (romiplostim): Risk of disease progression of pre-existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)

Contact

Social media

Unternavigation aller Website-Bereiche

Fast Accesses

BfArM - Federal Institute for Drugs and Medical Devices

Dear Doctor Letter (Rote-Hand-Brief) on Nplate® (romiplostim): Risk of disease progression of pre-existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)

Photo credits

Contact

Social media

Dear Doctor Letter (Rote-Hand-Brief) on Nplate^® (romiplostim): Risk of disease progression of pre-existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)